NCT06547502

Pharmacokinetics and Safety Profile of a Single Dose GZR4 in Subjects with Renal Impairment

The Study of Pharmacokinetics and Safety of a Single Dose of GZR4 Injection in Subjects with Mild to Moderate Renal Impairment and Subjects with Normal Renal Function

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Gan and Lee Pharmaceuticals, USA · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

This study will be conducted to investigated the effect of decreased kidney function on PK and safety of GZR4 and to guide dosing recommendations in people with kidney impairment.

Conditions

• Diabetes

Interventions

Type	Name	Description
DRUG	GZR4	single dose

Timeline

• Start date: 2024-07-03
• Primary completion: 2024-08-20
• Completion: 2024-09-05
• First posted: 2024-08-09
• Last updated: 2024-12-09

Locations

1 site across 1 country: China